Losartan Potassium
Product Images NDC 53002-3638

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-3638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530023638)

Losartan Potassium 100mg tablets packaging label from RPK Pharmaceuticals, Inc., containing 100 tablets. The label shows dosage instructions to take one tablet daily or as directed, along with prescription-only designation and space for patient and prescribing information. The label includes lot number, expiration date, billing NDC details, and barcodes.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoints over a 60-month study period between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Losartan Potassium versus Atenolol. The graph shows cumulative incidence increasing over time, with Atenolol higher than Losartan Potassium, indicating an adjusted risk reduction noted at the bottom of the graph.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure displaying primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol event rates as percentages, including hazard ratios with 95% confidence intervals. It features data split by overall results, age, gender, race, ISH, diabetes, and history of CVD, depicting both primary composite events and stroke (fatal/non-fatal) outcomes with visual markers representing hazard ratios.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph depicting the percentage of patients with an event over 48 months, comparing Losartan Potassium to placebo. The graph shows a risk reduction of 16.1% with Losartan Potassium, with a p-value of 0.022, indicating statistical significance.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular arrangement including chlorothiazole and biphenyl components with a potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.